A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I study. This study is the first time that a new experimental drug called
18FFluoroglutamine, or F-Glutamine, is being used in people. F-Glutamine is a drug designed
to be used with PET scanners that can 'see' where F-Glutamine goes in the body, after its
injected. PET scanners are one of the kinds of scanners you normally find in a hospital
radiology department. The researchers have found that tumors in animals absorb F-Glutamine.
The researchers believe that scans with F-Glutamine might be able to find tumors in patients.
This first in-human study is being done to see how long F-Glutamine lasts in the blood, when
it is given to people in tiny amounts by an injection, and to see where F-Glutamine goes in
the body. If the results of this trial are good, then the study doctors plan to use
F-Glutamine in another trial to see if scans with F-Glutamine are better for finding tumors
compared to the standard types of scans that doctors use.